bio chat
For Shire, it’s
critical that we are
a catalyst in creating
an environment
that supports rare
disease patients with
a comprehensive
program that
will encompass
awareness, education,
diagnosis, and
infrastructure
geographical expansion to continue
building global brands across
portfolios. We intend to expand
therapeutic area leadership and to
broaden our portfolio of best-in-
class products. We also aim to focus
on the effective execution of our late
stage clinical development pipeline
in order to support future growth.
What are the current
important business activities
of Shire in India?
Shire as an entity is advocating
national policy development
44
BioVoiceNews | October 2017
that supports improved access to
healthcare and health innovations
for those with rare diseases. To
help make rare diseases a public
health priority, the company
collaborates with the rare disease
community and other stakeholders.
Drawing on our experience in
enabling the provision of access
to diagnosis and treatment of
haemophilia, we plan to play a
similar role in the treatment of
lysosomal storage disorders. Shire’s
extensive portfolio means we have
the potential to help thousands
of patients who need treatments
especially for therapies that are
not yet available in India. We
want to make therapies accessible
to patients so that they can start
leading a near normal life.
We also plan to bring our oncology
portfolio into the country, including
a first in line treatment for acute
lymphoblastic leukemia.
For Shire, it’s critical that we are a
catalyst in creating an environment
that supports rare disease patients
with a comprehensive program
that will encompass awareness,
education, diagnosis, and
infrastructure to provide the right
treatment options. We believe the
only way to make this possible is